|
3172 Porter Dr. Palo Alto, CA 94304 CA Tel. 650-384-8500 Fax 650-858-0390 |
Type: Subsidiary
On the web:
http://www.gilead.com/cvt.html
Employees:
550
Employee growth: 6.6%
Gilead Palo Alto (formerly CV Therapeutics) is honed in on cardiovascular research. The drug development company specializes in pharmaceuticals to treat chronic cardiovascular diseases. The firm's drug Ranexa, licensed from a Roche subsidiary, is FDA-approved as a first-line and second-line treatment for patients with chronic angina (chest pain). Gilead Palo Alto won approval for its cardiac imaging agent, Lexiscan, in 2008; the drug is marketed by Astellas Pharma. The company is developing potential therapies for ailments including heart failure and atrial fibrillation (irregular heartbeat). Gilead Palo Alto changed its name from CV Therapeutics after being acquired by Gilead Sciences in 2009.
Key numbers for fiscal year ending December, 2008:
Sales: $154.5M
One year growth: 86.5%
Net income: ($98.5)M
Officers:
Chairman, CEO, and Chief Science Officer: Louis G. Lange
SVP Operations: David Banks
SVP and CFO: Daniel K. (Dan) Spiegelman
Competitors:
AstraZeneca
Sciele Pharma
Valeant
